Vericel

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vericel (VCEL) reports robust Q4 earnings and eyes market expansion

Vericel (VCEL) closed 2022 with strong financial and business results, setting the stage for continued growth and profitability in 2023.
The company's focus on innovation, market expansion, and financial discipline underscores its commitment to long-term success.
Despite challenges in regulatory approvals and operational timelines, Vericel (VCEL) remains optimistic about its growth prospects and market positioning.

Vericel reports robust Q1 earnings, raises revenue guidance significantly

Vericel's Q1 performance reflects resilience and growth, with a focus on expanding revenue streams and market presence through product development and commercialization efforts.
While facing challenges in managing expenses and achieving profitability, the company's strong financial position and revenue guidance revisions signal confidence in its growth trajectory.
By capitalizing on MACI's success, navigating upcoming product launches, and maintaining financial discipline, Vericel is poised for continued success and market expansion in the regenerative medicine space.

Vericel reports robust Q2 earnings, eyes growth through new products

Vericel's strong Q2 performance and raised revenue guidance indicate a positive outlook for the company.
Challenges with NexoBrid distribution and MACI conversion rates require focused strategies for growth.
Opportunities lie in upcoming product launches and targeted sales approaches to drive revenue growth.

Vericel reports record Q3 revenue, raises guidance for 2023

Vericel's Q3 performance was exceptional, setting the stage for continued growth.
The company's strong financial position and product strategies bode well for future success.
Anticipated revenue growth in 2024 and expansion plans signal positive momentum.
Vericel aims for a robust finish in 2023 and sustained growth in 2024.

Vericel (VCEL) posts record Q4 revenue, eyes sustained growth

Vericel (VCEL) delivered robust financial results in Q4 2023, with strong revenue growth, operational efficiency, and positive market feedback on key products.
The company is well-positioned for future growth with new product launches, improved margins, and resolved customer dynamics enhancing market stability.
While challenges exist in maintaining growth momentum and managing quarterly margins, strategic investments and market opportunities offer avenues for sustained success.

Vericel (VCEL) posts stellar Q1 results, eyes market expansion

Vericel delivered a robust performance in Q1 2024, marked by revenue growth, profitability surge, and raised full-year guidance.
The company's strengths lie in margin expansion efforts, strategic investments, and plans for market expansion through new initiatives and surgeon targeting.
Challenges include balancing expenses with profitability targets and ensuring rapid adoption of new products among diverse surgeon segments.
Opportunities abound in operational efficiencies, market expansion strategies, and potential for accelerated growth based on product advantages and market positioning.

Vericel reports record Q2 revenue, eyes growth through new launches

Vericel delivered a strong performance in Q2 2024 with record revenue and profitability, driven by MACI and operational efficiency.
While facing challenges with Epicel revenue variability, the company remains optimistic about growth opportunities and market expansion.
With a focus on product launches, FDA approvals, and financial strength, Vericel is well-positioned for continued growth and success in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 39th Annual J.P. Morgan Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Thursday, January 14, 2021 at 11:40 a.m. Eastern Time.

Vericel to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021

Vericel is a low-risk, high-quality small biotech with high growth potential. The business is already profitable with 70% gross profit margin and no debt on the balance sheet.

Vericel: A Rare, High-Quality Small Biotech With Rapid Growth Ahead

Vericel Corporation (VCEL) CEO Nick Colangelo on Q3 2020 Results - Earnings Call Transcript

Total Net Revenues of $32.3 Million and Net Income of $3.6 Million

Vericel Reports Record Third Quarter Revenues and Net Income

Exact Sciences

Inmode Ltd

Invesco QQQ

Technology Select Sector SPDR Fund

Technology won't always be on top. There's a bunch of budding industries that could prove to be winners over the next 5 years.

Stock Investors: What's the Next Hot Industry?

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced presentations at the following upcoming investor conferences.

Vericel to Present at Upcoming Investor Conferences

Vericel Corp (VCEL) has been struggling lately, but the selling pressure may be coming to an end soon.

Vericel Corp (VCEL) Sees Hammer Chart Pattern: Time to Buy?

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2020 financial results and business highlights.

Vericel to Report Third-Quarter 2020 Financial Results on November 5, 2020

Double-Digit Revenue, Implant and Biopsy Growth for MACI in the Quarter and Record Monthly Biopsies in September

Vericel Announces Preliminary Third Quarter 2020 Total Net Revenues of $32 Million

CAMBRIDGE, Mass., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, will host a virtual Analyst and Investor Day on Friday, October 16, 2020, from 9:00 a.m. - 11:00 a.m. ET. During the event, Vericel executives will provide a general business update as well as current U.S. commercialization plans for NexoBrid® (concentrate of proteolytic enzymes enriched in bromelain). Additionally, burn surgeon thought leaders will discuss current burn debridement practices and how NexoBrid, upon approval by the U.S. Food and Drug Administration (FDA), could change the current treatment paradigm for debridement of severe thermal burns.

Vericel To Host Virtual Analyst and Investor Day on October 16, 2020

CAMBRIDGE, Mass., Sept.  16, 2020  (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the recently submitted Biologics License Application (BLA) for NexoBrid® (concentrate of proteolytic enzymes enriched in bromelain) for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of June 29, 2021. In addition, the FDA communicated that it is not currently planning to hold an advisory committee meeting to discuss the application. 

Vericel Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

CAMBRIDGE, Mass., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced presentations at multiple upcoming investor conferences.

Vericel to Present at Multiple Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept.  04, 2020  (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 18th Annual Morgan Stanley Global Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Thursday, September 17, 2020 at 2:45 p.m. Eastern Time.

Vericel to Present at the 18th Annual Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2020

MediWound

YAVNE, Israel and CAMBRIDGE, Mass., Aug.  25, 2020  (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, has accepted the first shipment of NexoBrid® (concentrate of proteolytic enzymes enriched in Bromelain) as part of its mission to build national preparedness for public health emergencies. The initial BARDA procurement of NexoBrid is valued at $16.5 million, which includes additional quarterly deliveries planned through the end of 2021. In addition, BARDA holds an option to procure additional quantities of NexoBrid through funding of up to $50 million.

MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness

Vericel Corporation (VCEL) CEO Nick Colangelo on Q2 2020 Results - Earnings Call Transcript

Product Revenues of $20.0 Million Reported for the Second Quarter

Vericel Reports Second Quarter 2020 Financial Results

CAMBRIDGE, Mass., July  22, 2020  (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2020 financial results and business highlights.

Vericel to Report Second-Quarter 2020 Financial Results on August 5, 2020

Investors need to pay close attention to Vericel (VCEL) stock based on the movements in the options market lately.

Do Options Traders Know Something About Vericel (VCEL) Stock We Don't?

Second Quarter Net Product Revenues Expected to be Approximately $20 Million Second Quarter Net Product Revenues Expected to be Approximately $20 Million

Vericel Announces Preliminary Second Quarter 2020 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., June  30, 2020  (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking the approval of NexoBrid® (concentrate of proteolytic enzymes enriched in Bromelain) for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.  NexoBrid is approved in the European Union and other international markets and has been designated as an orphan biologic in the United States, European Union and other international markets.  Vericel holds an exclusive license for North American commercial rights to NexoBrid.  Funding and technical support to MediWound Ltd. for development of NexoBrid is provided by the U.S. Biomedical Advanced Research and Development Authority (BARDA).

Vericel Announces Submission of Biologics License Application to the FDA for NexoBrid for the Treatment of Severe Thermal Burns

Cinemark Holdings

IDEXX Laboratories

Myriad Genetics

Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.

Dump These 4 Toxic Stocks or Sell Short for Timely Profits

Vericel's (VCEL) CEO Nick Colangelo on Q1 2020 Results - Earnings Call Transcript

Vericel Corporation: A Must-Have Biotech Post-COVID-19 Sell-Off - Behind The Idea

Vericel Is Substantially Undervalued Given Strong Balance Sheet, Profitability And Competitive Advantages

First Majestic Silver

Casella Waste Systems

Envestnet

Accurately identifying toxic stocks and abandoning or short selling those at the right time is the key to safeguard your portfolio from big losses.

News for Vericel Stock (VCEL)